Final submission of IEEE EMBS Manuscript - Strategies for delivery of non-viral plasmid DNA based gene therapy.pdf (1.09 MB)
The arrival of genetic engineering: strategies for delivery of nonviral plasmid DNA-based gene therapy
journal contributionposted on 2013-10-15, 13:25 authored by Eugene R. Arulmuthu, David Williams, Hendrik Versteeg
The delivery of a therapeutic gene inserted in a vector for somatic gene therapy holds great promise for the future. Encouraging results from the clinical trials of first-generation plasmid-based medicines/ vaccines have further validated the importance of molecular biology and biotechnology research. With newer developments in bioengineering for the mass production and purification of plasmid DNA, gene therapy using non-viral vectors offers opportunities for multiple therapeutic benefits in the healthcare industry. However, low therapeutic success rates due to inefficient delivery systems have blunted the success of gene therapy. This paper examines the status of plasmid DNA in the gene therapy clinical trials, challenges and advances in plasmid DNA based non-viral gene delivery through the different routes of administration, and focuses on the pulmonary route for aerosol gene delivery.
- Mechanical, Electrical and Manufacturing Engineering
CitationARULMUTHU, E.R., WILLIAMS, D.J. and VERSTEEG, H.K., 2009. The arrival of genetic engineering: strategies for delivery of nonviral plasmid DNA-based gene therapy. IEEE Engineering in Medicine and Biology Magazine, 28 (1), pp.40-54.
- AM (Accepted Manuscript)
Notes© 2009 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works.